Review
Copyright ©The Author(s) 2021.
World J Diabetes. Nov 15, 2021; 12(11): 1832-1855
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1832
Table 1 Examples of antimicrobial activities of some antidiabetic drugs
Antidiabetic drug
Antimicrobial activity
Proposed mechanism
Ref.
MetforminAntibacterialActivation of the AMPK-mediated phagocytosis and production of mROS[170]
Disruption of the outer membrane permeability[170]
Down regulation of the Q.S encoding genes and mitigate the bacterial virulence[19,186]
Anti-TBIncreasing the production of β-defensin-2, -3 and -4 which diminish bacterial growth and multiplication[178]
Inhibition of mitochondrial complex-I which is analogous to mycobacterial NDH-I complex[176]
Activation of T regulatory and CD8 memory T cells responses activity[177]
SitagliptinAntibacterialDownregulation of the Q.S encoding genes, occupy the Q.S receptors and diminish bacterial virulence[18,19,186]
Anti-COVID-19Reduction of the inflammation intensity[190,191]
Targeting viral proteins[192]
Binding to viral spikes[193]
AntibiofilmTargeting enzyme XPDAP, analogous to mammalian enzyme DPP IV[187]
Vildagliptin AntibiofilmTargeting enzyme XPDAP, analogous to DPP IV[187]
Anti-amoebic-[188]
SaxagliptinAntibiofilmTargeting enzyme XPDAP, analogous to DPP IV[187]
PioglitazoneAntibacterialIncreasing phagocytosis and production of reactive oxygen species in phagocytes[197,198]
TolbutamideAntibacterial and antifungal -[205]
2nd generation sulfonylureasAntifungalInhibition of the NLRP3 inflammasome[206]
AntibacterialPrevention of inflammasome effector IL-1β[207]
GlimepirideAnti-amoebic -[188]
RepaglinideAnti-amoebic -[188]
Glucagon-like Peptide-1In HIV treatmentReduction of HIV-associated metabolic adverse effects[212]
α-glucosidase inhibitorsAntibacterialTargeting bacterial glucosidase[220]
Antiviral and anti-COVIDAlter glycosylation in viral life cycle[221]